REBECA: A phase I study of bevacizumab (BEV) and whole-brain radiation therapy (WBRT) for treatment of solid tumors brain metastases (BM), EudraCT: 2009-015977-11

Authors :: D. Allouache
Iona Hrab
Joelle Lacroix
Youlia M. Kirova
François Campana
Louis Gras
Marie-Pierre Sunyach
Audrey Emmanuelle Dugué
Bénédicte Clarisse
Julien Geffrelot
Jean-Marc Constans
Jean-Michel Grellard
Marc-André Mahé
C. Hanzen
Emilie Le Rhun
Christelle Levy
Xavier Paoletti
Katharina Gunzer
Stéphane Supiot
Marianne Leheurteur
Source :: Journal of Clinical Oncology. 32:2054-2054
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2054 Background: BM, the most frequent malignancy in the central nervous system, remains of poor prognosis. Standard treatment is WBRT. Neo-angiogenesis plays an important role in BM growth. Angiog...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Poor prognosis
Bevacizumab
business.industry
Standard treatment
Central nervous system
Malignancy
medicine.disease
Phase i study
medicine.anatomical_structure
Internal medicine
Medicine
business
Whole brain radiation therapy
medicine.drug

Full Text Access

Tools